Stroke Prevention 
The MD Magazine Stroke Prevention condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.


Direct Oral Anticoagulants vs. Warfarin for Reducing Stroke, Major Bleeding
Compared with warfarin, are direct oral anticoagulants (DOACs), including apixaban, dabigatran, and rivaroxaban, better at reducing stroke and major bleeding risks in patients with non-valvular atrial fibrillation? Alpesh Amin, MD, professor of medicine at the University of California, Irvine breaks it down at ACC 2017 in Washington, District of Columbia.
In patients with AFib, digoxin should not be a first-line drug.
Heart damage after non-cardiac surgery is usually missed. A test finds it.
In the first head to head trial, rivaroxaban was more effective than aspirin.
A synthetic version of "good" cholesterol failed to clear blocked arteries.
Bleeding complications with rivaroxaban no worse than with aspirin.
Paul Burton, MD, PhD, revealed results from the phase 3 EINSTEIN CHOICE trial at the 66th Scientific Session of the American College of Cardiology (ACC 2017) in Washington, District of Columbia. The trial examined the use of rivaroxaban (Xarelto/Janssen) or aspirin as extended treatment in patients with VTE.
Details on why Pfizer pulled its PCSK9 inhibitor seen in SPIRE studies.
Janssen halted a trial of a cardiac drug early because it worked.

Most Popular


$vacMongoViewPlus$ $vAR$